Hypofibrinogenemia associated with vincristine and prednisone therapy in lymphoblastic leukemia

Hamid Al‐Mondhiry

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Three patients with acute lymphoblastic leukemia and one with lymphosarcoma cell leukemia developed transient hypofibrinogenemia during a course of treatment with vincristine and prednisone. There was no evidence of overt, disseminated intravascular coagulation or significant liver impairment. Fibrinogen survival using homologous125I‐labelled fibrinogen was measured in two patients; it was moderately shortened in both, perhaps indicating subclinical intravascular coagulation. Rapid lysis of leukemic cells might have been responsible for activating coagulation and fibrinolysis in vivo. These four patients, however, were not different in any clinical or laboratory parameter from nine others with lymphoblastic leukemia similarly treated and investigated without observing any defect in their fibrinogen. There were no bleeding complications and the fibrinogen level became normal within 13 to 30 days.

Original languageEnglish (US)
Pages (from-to)144-147
Number of pages4
JournalCancer
Volume35
Issue number1
DOIs
StatePublished - Jan 1975

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Hypofibrinogenemia associated with vincristine and prednisone therapy in lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this